Use of Botulinum Toxin A to Treat Chemotherapy-Induced Raynaud's Phenomenon.

Autor:	Potluri TK; Department of Plastic Surgery and Reconstructive Medicine, University of South Florida Morsani College of Medicine, Tampa, USA., Lee FG; Department of Plastic Surgery and Reconstructive Medicine, University of South Florida Morsani College of Medicine, Tampa, USA., Song E; Department of Plastic Surgery and Reconstructive Medicine, University of South Florida Morsani College of Medicine, Tampa, USA., Wallace SJ; Division of Plastic & Reconstructive Surgery, Lehigh Valley Health Network, Allentown, USA., Miller N; Division of Plastic & Reconstructive Surgery, Lehigh Valley Health Network, Allentown, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2021 Jan 05; Vol. 13 (1), pp. e12511. Date of Electronic Publication: 2021 Jan 05.
DOI:	10.7759/cureus.12511
Abstrakt:	Raynaud's phenomenon (RP) is a vasospastic disorder of the digital blood vessels leading to pain, paresthesias, and pallor in response to cold or stress. RP can develop secondary to a number of pathologies or factors, including the use of chemotherapy agents. Typical first-line therapies for secondary RP may be contraindicated in patients with certain comorbidities. Here, we discuss a case in which botulinum toxin A (BTX-A) was used to treat chemotherapy-induced RP in a patient with non-small cell lung cancer (NSCLC). We provide a review of the existing literature on the clinical course and treatment modalities, including the use of BTX-A, for patients with secondary RP. A 56-year-old female with NSCLC received treatment with bevacizumab and pemetrexed. Her initial symptoms included progressive discoloration and pain in her fingertips, which hastily progressed to ischemia and subsequent dry gangrene. She was diagnosed with chemotherapy-induced RP, but traditional management options were complicated by acute congestive heart failure. BTX-A injections were administered at key locations on the wrist and hand, significantly improving her symptoms and slowing the progression of the gangrenous changes. RP can develop as sequelae of chemotherapy regimens. Clinical management may be complicated by underlying pathology and/or patient symptoms. BTX-A injections are an excellent non-operative therapeutic option for patients with secondary RP in cases where mainstay therapies may be contraindicated, thus decreasing pain, improving patient quality of life, and slowing the progression of gangrenous changes. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Potluri et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu